OncoGenex Pharmaceuticals, Inc. OGXI announced today the
initiation of ENSPIRIT, a Phase 3 trial evaluating custirsen for the treatment
of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who
have progressed after initial chemotherapy treatment has failed. The trial
will investigate if combining custirsen with docetaxel, a standard second-line
NSCLC chemotherapy, has the potential to improve survival outcomes compared to
docetaxel alone in these patients. Two formal interim analyses are planned
for stopping the trial early based on inadequate evidence of clinical benefit
or futility. No interim analyses for claiming efficacy are planned.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in